Home
About
- Directors and Management
- Careers
Corporate Governance
Investors
- Public Disclosure Policy
- ASX Announcements
  - 2023
  - 2022
  - 2021
  - 2020
  - 2019
  - 2018
  - 2017
  - 2016
  - 2015
  - 2014
  - 2013
  - 2012
  - 2011
  - 2010
  - 2009
  - 2008
- Financial Information & Reports
- Share Registry Information
- Analyst Coverage
- Share Information
- Anagenics in the media
- Newsletter Archive
Contact

✕

Preclinical Study Shows Reduction in Disease Severity

Home
Preclinical Study Shows Reduction in Disease Severity

Published by Tiffany McMillan on November 18, 2019

Categories

Tags

Share

Tiffany McMillan

ANAGENICS LIMITED

ASX: AN1

Suite 204, Level 2
55 Clarence Street
Sydney NSW 2000
Australia

Today’s Share Price

Latest ASX Announcements

21/02/2023 - Despatch of Retail Offer Booklet

21/02/2023 - Entitlement Offer – Letter to Ineligible Shareholders

17/02/2023 - Application for quotation of securities – AN1

*Anagenics was formerly Cellmid Limited (ASX:CDY)
© 2023 Anagenics Limited. All Rights Reserved. ABN 69 111 304 119.
Careers | Privacy Policy | Contact Us | Subscribe